Top Links You Must Click On
From the Wires
Dr. Michael Har-Noy to Present at the Inaugural European Immunotherapy and Cancer Vaccine Congress in Brussels, Belgium
By: Marketwired .
Nov. 27, 2012 07:35 AM
NEW YORK, NY -- (Marketwire) -- 11/27/12 -- Immunovative, Inc. ("IMUN" or the "Company") (OTCQB: IMUN) announces today that Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies, Ltd. ("ITL") was invited to speak at the inaugural Immunotherapies and Cancer Vaccine Congress to be held at the Sheraton Brussels Hotel on December 5-6 in Brussels, Belgium (the "Congress"). Dr. Har-Noy will be joining industrial and academic leaders in immunotherapy and cancer vaccine development to discuss the latest ideas on how to maximize the immune response to cancer, optimize the clinical development timelines of immunotherapy drugs and boost the commercial success of immunotherapies.
The recent FDA approvals of Dendreon's Provenge cancer vaccine for prostate cancer and Bristol Myers Squibb's Yervoy immunotherapy drug for melanoma has sparked a resurgence of interest in immunotherapies and cancer vaccines. The organizer of the Congress, Informa Life Sciences, predicts that by 2014 that 3 of the top 10 cancer drugs will be immunotherapy drugs. Major pharmaceutical companies are launching immunotherapy drug development programs to enter this lucrative market and many of the leading companies are making presentations at the Congress. A full program can be viewed on-line at:
Dr. Har-Noy will be speaking at the Novel Approaches for Enhancing the Immune Response session held on December 5. The title of his presentation is: "Harnessing the power of the graft vs. tumor effect of non-myeloablative allogeneic stem cell transplants to enhance the effectiveness of cancer vaccine strategies."
Cancer vaccines are a promising new approach for cancer treatment. However, while autologous, patient-specific, anti-tumor vaccine protocols have been shown to elicit increased titers of tumor-specific immune cells, only a small portion of these vaccinated patients demonstrate clinical benefit. The minimal clinical benefits from these tumor vaccine strategies have been attributed to tumor immunoavoidance mechanisms and tumor-influenced activation of immunosuppressive circuits, including induction of FoxP3+ regulatory T cells (Treg) and loss of cellular immunity. While the efficacy of anti-cancer vaccines is hampered by these mechanisms, these mechanisms have been shown to be overcome in the setting of allogeneic hematopoietic cell transplantation (allo-HCT) where the immune-mediated graft vs. tumor effect (GVT) represents a curative mechanism for many patients with advanced hematological malignancies and has also been shown to be capable of debulking chemotherapy-resistant metastatic disease. This GVT effect has been described as the most powerful and most effective anti-tumor mechanism ever discovered in humans.
However, the clinical applicability of the GVT effect is severely limited due to the morbidity and mortality of the related immune-mediated effect known as graft vs. host disease (GVHD) which occurs when engrafted donor cells attack the normal tissues of the host. The GVT and GVHD effects are intimately linked and attempts to separate these effects have been difficult to demonstrate in the clinic. ITL's Mirror Effect technology is believed to be the first clinical evidence of harvesting the power of the GVT mechanism without GVHD toxicity.
Dr. Har-Noy stated: "I will be discussing at the Congress the potential for our Mirror Effect technology and our lead AlloStim immunotherapy drug candidate to work as an adjuvant to enhance the efficacy of cancer vaccines. I will present supporting data from our first human trials of AlloVax to demonstrate the power of AlloStim in combination with a tumor antigens to enhance immune response and overcome tumor immunoavoidance mechanisms. I look forward to networking with leaders in cancer vaccine development in order to establish the relationships that could eventually lead to collaborations, licensing or other joint development efforts."
Seth Shaw, CEO of IMUN, stated: "We are honored that our technology was selected by the organizers as a leading example of a novel approach to enhance the immune system. We look forward to increasing the awareness of our technology in Europe and in the networking opportunities available at the Congress. We are seeking partners with vaccine technology platforms that could be enhanced when combined with AlloStim. This Congress will serve to introduce our technology to leaders in the European cancer vaccine business community and is also an opportunity for us to learn more about the technologies and development efforts of leading companies in the cancer vaccine field."
About Immunovative, Inc.:
About Immunovative Therapies, Ltd.:
Enterprise Open Source Magazine Latest Stories . . .
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
SYS-CON Featured Whitepapers
Most Read This Week